Lipitor's Chemical Structure
Lipitor (atorvastatin calcium) is a synthetic statin with the chemical formula C33H35FN2O5 (free acid form). Its structure features a core 3,5-dihydroxyhept-6-enoic acid chain, a pyrrole ring substituted with a fluorophenyl group, and a complex side chain including a piperazinone moiety.[1]
<br />
O<br />
//\\<br />
/ \<br />
| |<br />
C C-OH<br />
/|\ /|\<br />
F-Ph pyrrole-piperazinone<br />
| |<br />
3,5-dihydroxyheptenoic acid chain<br />
(Simplified skeletal formula; full IUPAC name: (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyhept-6-enoic acid.)
How It Inhibits HMG-CoA Reductase
Lipitor competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, by mimicking its natural substrate HMG-CoA. The 3,5-dihydroxyhept-6-enoic acid moiety acts as the pharmacophore, binding to the enzyme's active site via hydrogen bonds with residues like Asp690 and Lys691. The planar pyrrole ring and lipophilic fluorophenyl group enhance hydrophobic interactions in the enzyme's pocket, stabilizing the complex and preventing substrate access. This lowers mevalonate production, reducing LDL cholesterol.[2][3]
Key Structural Features Driving Potency
- Dihydroxyheptanoate chain: Provides electrostatic mimicry of HMG-CoA's carboxylate and hydroxyl groups for tight binding (Kd ~5 nM).
- Fluorophenyl substitution: Increases lipophilicity, improving membrane permeability and hepatic selectivity over muscle tissue.
- Pyrrole core with isopropyl: Boosts steric fit and enzyme affinity compared to earlier statins like lovastatin, making Lipitor ~100x more potent.[4]
Comparison to Other Statins
Unlike simvastatin's hexahydronaphthalene ring, Lipitor's pyrrole system allows a more rigid, optimal conformation for the active site. Pravastatin lacks the lipophilic phenyl groups, reducing potency. Rosuvastatin's pyrimidine achieves similar inhibition but with higher polarity for renal clearance.[5]
Structural Modifications and Patents
Pfizer patented atorvastatin in 1986 (US Patent 4,681,893), emphasizing the pyrrole-fluorophenyl combo for enhanced inhibition. Exclusivity ended in 2011; generics replicate the structure exactly. No major variants alter the core pharmacophore.[6]
Sources
[1]: PubChem - Atorvastatin
[2]: Istvan & Deisenhofer, Science (2001) (crystal structure)
[3]: DrugBank - Atorvastatin
[4]: Kathawala, Med Res Rev (1991)
[5]: Schachter, Fundam Clin Pharmacol (2005)
[6]: DrugPatentWatch.com - Lipitor Patents